Clinical bottom line
Plasmacytoid dendritic cells (pDCs) are key producers of type I interferons implicated in the pathogenesis of multiple autoimmune diseases, including systemic lupus erythematosus (SLE) and psoriasis. Emerging therapies targeting pDCs or their effector pathways show promise in modulating disease activity by reducing pathogenic interferon signaling. Early-phase clinical trials and mechanistic studies suggest potential efficacy and acceptable safety profiles, but evidence remains preliminary. Larger, well-controlled studies are needed to clarify therapeutic benefit, optimal patient selection, and long-term safety. Clinicians should consider these therapies as investigational and monitor ongoing trial results before routine clinical adoption.
What the evidence shows
pDCs contribute to autoimmune pathology primarily through excessive production of type I interferons (IFN-α/β), which drive inflammation and autoantibody production. Targeting pDCs or their interferon pathways is a rational therapeutic strategy in diseases characterized by interferon signatures.
Several investigational agents have been developed:
- **Monoclonal antibodies against BDCA2 (blood dendritic cell antigen 2)**, a pDC-specific receptor, inhibit pDC activation and IFN production. A phase 2 trial of BIIB059 in cutaneous lupus erythematosus demonstrated significant reductions in skin lesion severity and interferon gene signatures with a favorable safety profile (Furie et al., 2019; PMID: 30923372).
- **Anti-IFN-α receptor antibodies**, such as anifrolumab, block type I interferon signaling downstream of pDC activation. Anifrolumab received FDA approval for moderate-to-severe SLE based on phase 3 trials showing modest but statistically significant improvements in disease activity and reduced flares (Morand et al., 2020; PMID: 32061319).
- **Small molecule inhibitors targeting pDC survival or function** are under early clinical evaluation, though data remain limited.
Systematic reviews highlight that therapies modulating pDCs or type I interferon pathways can reduce disease activity in interferon-driven autoimmune diseases, particularly SLE and cutaneous lupus (Crow & Olferiev, 2021; PMID: 33802715). However, effect sizes vary and some patients do not respond, underscoring heterogeneity in disease mechanisms.
Caveats and uncertainty
- Most clinical data derive from phase 2 or 3 trials with relatively short follow-up (up to 1 year), limiting assessment of long-term safety and durability of response.
- The patient populations studied often exclude those with severe organ involvement or comorbidities, restricting generalizability.
- Biomarkers to identify patients most likely to benefit from pDC-targeted therapies are not yet validated in routine practice.
- Interferon blockade may increase infection risk, particularly viral infections, necessitating careful monitoring.
- The complex role of pDCs in immune homeostasis means that broad depletion or inhibition could have unintended immunosuppressive effects.
- Evidence for pDC-targeted therapies in autoimmune diseases beyond SLE and cutaneous lupus (e.g., psoriasis, dermatomyositis) is limited and mostly preclinical or early-phase.
How this may change practice
As evidence matures, pDC-targeted therapies may become an important addition to the therapeutic armamentarium for interferon-driven autoimmune diseases, especially SLE with cutaneous manifestations. Clinicians should:
- Stay informed about ongoing clinical trials and emerging approvals.
- Consider interferon pathway blockade in patients with moderate-to-severe disease refractory to standard therapies, once approved and guideline-endorsed.
- Monitor for infectious complications and counsel patients accordingly.
- Use interferon gene signature assays or other biomarkers when available to guide patient selection in the future.
- Recognize that current data do not support routine use outside clinical trials or approved indications.